70	J1049
四	U.S.
<u> </u>	PIO

Please type a plus sign (+) inside this box — 🛨

PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## UTILITY **PATENT APPLICATION TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorr	ey Docket No.	DYX-016.1 US		
First Inventor		Rondon & Ladner		
	BINI	DING PEPTIDES FOR		
Title	Title CARCINOEMBRYONIC ANTIGEN (CE)			
Expre	ss Mail Label No	EL 164335061 US		

APPLICA1	TION ELEMENTS	ADD		tant Comi Patent Api		ner for Patents
See MPEP chapter 600 conce	erning utility patent application conten			nington, D		
1. Fee Transmittal For (Submit an original and a di	rm (e.g., PTO/SB/17) uplicate for fee processing)	7.	CD-ROM or CD-R in			table or
2. Applicant claims sn See 37 CFR 1.27.	mall entity status.  8. Nucleotide and/or Amino Acid Sequence Submission					
3. Specification (preferred arrangements	[Total Pages 56]	a. [	Computer Readable		RF)	
- Descriptive title of	of the invention	b. :	Specification Sequence I	isting on:		
- Cross Reference - Statement Rega	to Related Applications rding Fed sponsored R & D		i. CD-ROM or	CD-R (2	copies	s); or
	uence listing, a table, ogram listing appendix	,	i i. 🗶 paper			
- Background of ti	ne Invention	C.	X Statements verifying	g identity	of abo	ove copies
- Brief Summary o - Brief Description	of the Invention of the Drawings (if filed)		CCOMPANYING A			
<ul> <li>Detailed Descrip</li> <li>Claim(s)</li> </ul>	tion	9.	Assignment Papers	•	eet &	
- Abstract of the D	Disclosure	10.	37 CFR 3.73(b) Sta (when there is an a			Power of Attorney
△ X Drawing(s) (35 U.	S.C. 113) Total Sheets 8	1 11.	English Translation	-	nt (if a <sub>l</sub>	
5. Oath or Declaration	12 V Information Disclosure Copies of ID:				Copies of IDS Citations	
Statement (IDS)/F10-1449						
Copy from a	Copy from a prior application (37 CFR 1.63 (d))					
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)						
named in the prior application, see 37 CFR 1 63(d)(2) and 1.33(b).  Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.				U.S.C. 122 form PTO/SB/35		
6. Application Data Sheet. See 37 CFR 1.76 17. Other:						
18. If a CONTINUING APPLIC	CATION, check appropriate box, and	supply the req	isite information below a	and in a p	relimir	ary amendment,
or in an Application Data She	Divisional Continuation-in-part (C	CIP)	of prior application No09	J	541	,345
Prior application information:	Examiner (not known)		Group Art Unit:		46	
For CONTINUATION OR DIVISION	ONAL APPS only: The entire disclosure the disclosure of the accompanying co	of the prior app	lication, from which an oa	th or decla hereby in	aration corpor	is supplied under ated by reference.
The incorporation can only be	relied upon when a portion has been ina	dvertently omit	ed from the submitted ap	olication p	arts.	:
	19. CORRESPONDENCE ADDRESS					
Customer Number or Bar Co	de Label (Insert Customer No. or Alta	ich bay sode label h	or <b>X</b>	Correspond	lence ad	idress below
Name	Leon R. Yankwich, Esq.					
	YANKWICH & ASSOCIA	ATES				
Address	130 Bishop Allen Drive		T	T		
City	Cambridge	State	Massachusetts	Zip C		02139
Country	U.S.A.	Telephone	(617) 491-4343	Fa	x	(617) 491-8801
Name (Print/Type)	Kenneth P. Zwicker	Reg	istration No. (Attorne)	//Agent)		43,310
Signature	0/-/			Date	03	April 2001

Burden Hour Statement: This form is estimated to the 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Art Unit: (not yet assigned)

Examiner: (not yet known)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Rondon & Ladner In re Application of:

Serial No.:

(not yet assigned)

Filed:

(concurrently herewith)

Entitled:

BINDING PEPTIDES FOR

CARCINOEMBRYONIC ANTIGEN (CEA)

CIP of U.S. Appln. Ser. No. 09/541,345, pending

Attorney Docket No.: DYX-016.1 US

Asst. Commissioner for Patents

**Box Patent Application** 

Washington, D.C. 20231



## UTILITY PATENT APPLICATION TRANSMITTAL:

Continuation-In-Part of U.S. Appln. Ser. No. 09/541,345, pending Prior Unit: 1646 Prior Examiner: (not yet known)

1. Fee Transmittal form PTO/SB/17 (in duplicate).

2. Utility Patent Application Transmittal form PTO/SB/05.

- 3. Application specification of <u>56</u> pages (including Claims and Abstract of the Disclosure).
- 4. Formal drawings (8 sheets).
- 5. Unexecuted Inventor's combined declaration for patent and power of attorney.
- 6. Sequence Listing;
  - (a) computer readable form (CRF), (b) paper copy, and (c) statement under 37 CFR 1.821(f).
- 7. Information Disclosure Statement (including form PTO-1449).
- 8. Return receipt post card.
- Check No. 2178 in the amount of \$ 2016.00 to cover the application filing fee.

Respectfully submitted

Leon R. Yankwish: Registration No. 30,237

Kenneth P. Zwicker, PhD; Registration No. 43,310

Attorneys for Applicant

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

# CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EL 164335061 US, in an envelope addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on the date indicated below.

03 April 2001

Date

Stephanie of Seicht

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 2016.0
-------------

Complete if Known		
Application Number	(not yet assigned)	
Filing Date	(concurrently herewith)	
First Named Inventor	Rondon & Ladner	
Examiner Name	(not known)	
Group Art Unit	1646	
Attorney Docket No.	DYX-016.1 US	

METHOD OF PAYMENT FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES		
indicated fees and credit any overpayments to:	Large Small		
Account 50-0268	Entity Entity Fee Fee Fee Fee Fee Description	Fee Paid	
Number	Code (\$) Code (\$)		
Account Yankwich & Associates	105 130 205 65 Surcharge - late filing fee or oath		
Name Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet		
Applicant claims small entity status.	139 130 139 130 Non-English specification		
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination		
2. X Payment Enclosed: (check # 2178)  X Check Credit card Money Order  Order	112 920* 112 920* Requesting publication of SIR prior to Examiner action		
E G Grader —	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action		
FEE CALCULATION	115 110 215 55 Extension for reply within first month		
1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month		
Large Entity Small Entity Fee Fee Fee Fee Description	117 890 217 445 Extension for reply within third month		
Code (\$) Code (\$) Fee Paid	118 1,390 218 695 Extension for reply within fourth month		
101 710 201 355 Utility filing fee 710.00	128 1,890 228 945 Extension for reply within fifth month		
106 320 206 160 Design filing fee	119 310 219 155 Notice of Appeal		
107 490 207 245 Plant filing fee  108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal		
	121 270 221 135 Request for oral hearing		
	138 1,510 138 1,510 Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 710.00	140 110 240 55 Petition to revive - unavoidable		
2. EXTRA CLAIM FEES	141 1,240 241 620 Petition to revive - unintentional		
Fee from Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)		
Total Claims 42 -20** = 22 X 18.00 = 396.00	143 440 243 220 Design issue fee		
Independent 11 - 3** = 8 X 80.00 = 640.00	144 600 244 300 Plant issue fee		
Multiple Dependent 270.00 = 270.00	122 130 122 130 Petitions to the Commissioner		
	123 50 123 50 Processing fee under 37 CFR 1 17(q)		
Large Entity Small Entity Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt		
Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)		
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection		
104 270 204 135 Multiple dependent claim, if not paid	(37 ČFR § 1.129(a))		
109 80 209 40 ** Reissue independent claims over original patent	149 710 249 355 For each additional invention to be examined (37 CFR § 1.129(b))		
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)		
and over original patent	169 900 169 900 Request for expedited examination of a design application		
SUBTOTAL (2) (\$)1306.00	Other fee (specify)		
**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)		

SUBMITTED BY			Complete (if applicable)		
Name (PrintlType)	Kenpeth P. Zwicker	Registration No. (Attorney/Agent)	43,310	Telephone	(617) 491-4343
Signature	Rea Total Sa	pracomojn gorio		Date	03 April 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: (not yet assigned)

Examiner: (not yet assigned)

In re Application of: Rondon & Ladner

Serial No.: (not yet assigned)

Filed: (concurrently herewith)

Entitled: BINDING PEPTIDES FOR

CARCINOEMBRYONIC

ANTIGEN (CEA)

CIP of U.S. Appln. Ser. No. 09/541,345, pending

Attorney Docket No.: DYX-016.1 US

Assistant Commissioner for Patents

Box Patent Application Washington, D.C. 20231

# <u>Transmittal of Sequence Listing, Computer Readable Form, and Amendment Pertaining</u> <u>Thereto For Invention Containing Nucleotide and/or Amino Acid Sequence</u> <u>Under 37 CFR §§1.821-1.825</u>

Sir:

Transmitted herewith please find: a diskette containing a computer readable form (CRF) copy of the Sequence Listing, and a paper copy of the Sequence Listing for the patent application filed currently herewith this paper.

Applicant has assigned a separate identifier to each of the 151 sequences disclosed, as required by 37 CFR §§1.821-1.825.

Applicant verifies the following:

- 1. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are the same in content, as required by 37 CFR §1.821(f);
- The enclosed Sequence Listing and the computer readable form of the Sequence Listing
  for the above-identified patent application contain no new matter and do not go
  beyond the original disclosure of the application, as required by 37 CFR §1.821(g);

3. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Respectfully submitted,

Leon R. Yankwich; Registration No. 30,237

Kenneth P. Zwicker, PhD; Registration No. 43,310

Attorneys for Applicant

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

#### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. **EL 164335061 US**, in an envelope addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on the date indicated below.

Date

O3 April 2001

Date

O4 Stephanic L. Leicht